Objective To observe the clinical curative effect of Zhikang Granules in the treatment of nonalcoholic fatty liver disease.Methods Eighty patients with nonalcoholic fatty liver disease admitted to Department of Integrated Chinese and Western Medicines,the Second Hospital of Hebei Medical University from October 2014 to October 2015 were randomly divided into the treatment group (42 cases) and the control group (38 cases).The control group was treated with Atorvastatin orally,while the treatment group was treated with Atorvastatin and Zhikang Granules orally.The course of the two groups was 12 weeks.Results The total effective rate of treatment group and control group was 92.86％,55.26％ respectively,the difference was statistically significant (P ＜ 0.05).After treatment,the levels of triacylglycerol,total cholesterol,glutamic oxalacetic transaminase,glutamic-pyruvic transaminase in the two groups were all lower than those before treatment (P ＜ 0.05),and the levels of triacylglycerol,total cholesterol,glutamic oxalacetic transaminase,glutamic-pyruvic transaminase in the treatment group after treatment were lower than those of control group,the differences were statistically significant (P ＜ 0.05).After treatment,the levels of insulin resistance index,fasting bloodglucose in the two groups were all lower than those before treatment (P ＜ 0.05),and the levels of insulin resistance index,fasting blood-glucose in the treatment group after treatment were lower than those of control group,the differences were statistically significant (P ＜ 0.05).After treatment,the subjective uncomfortable symptoms of giddiness and tinnitus,fullness in the head,chest distress in the two groups were significantly improved compared with those before treatment (P ＜ 0.05),and the improvement of treatment group was significantly better than that of control group (P ＜ 0.05).Conclusion The curative effect of Zhikang Granules in the treatment of nonalcoholic fatty liver disease is distinct,which is worthy of clinical promotion and application.%目的 观察脂康颗粒治疗非酒精性脂肪肝的临床效果.方法 将2014年10月～2015年10月河北医科大学第二医院中西医结合内科收治的80例非酒精性脂肪肝患者随机分为治疗组(42例)和对照组(38例).对照组给予口服阿托伐他汀,治疗组给予口服阿托伐他汀和脂康颗粒,两组疗程均为12周.结果 治疗组和对照组的治疗总有效率分别为92.86％和55.26％,差异有统计学意义(P＜0.05).两组治疗后三酰甘油、总胆固醇、谷草转氨酶、谷丙转氨酶水平均明显低于治疗前(P＜0.05),且治疗组治疗后三酰甘油、总胆固醇、谷草转氨酶、谷丙转氨酶水平明显低于对照组,差异有统计学意义(P＜0.05).两组治疗后胰岛素抵抗指数、空腹血糖均明显低于治疗前(P＜0.05),且治疗组治疗后胰岛素抵抗指数、空腹血糖明显低于对照组,差异有统计学意义(P＜0.05).两组治疗后眼花耳鸣、头胀、胸闷等自觉不适症状均较治疗前明显改善(P＜0.05),且治疗组治疗后改善情况显著优于对照组(P＜0.05).结论 脂康颗粒治疗非酒精性脂肪肝效果显著,值得临床推广应用.
展开▼
